Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients
We investigated whether serum tumor markers (STMs) represent a valuable noninvasive tool to predict epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients. A retrospective analysis was performed for 143 NSCLC patients at the Peking University International H...
Gespeichert in:
| Veröffentlicht in: | Annals of diagnostic pathology 2020-12, Vol.49, p.151633-151633, Article 151633 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151633 |
|---|---|
| container_issue | |
| container_start_page | 151633 |
| container_title | Annals of diagnostic pathology |
| container_volume | 49 |
| creator | Wen, Linfang Wang, Shenghao Xu, Weiran Xu, Xiaofeng Li, Mei Zhang, Yaqiong Du, Xiaobing Liu, Shuang |
| description | We investigated whether serum tumor markers (STMs) represent a valuable noninvasive tool to predict epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients.
A retrospective analysis was performed for 143 NSCLC patients at the Peking University International Hospital from December 2014 to December 2019. EGFR mutations in the tumor tissues were identified by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and next generation sequencing (NGS). The relationships between EGFR mutation and several clinicopathological features were analyzed.
EGFR mutation were found more frequently in female (56.67%, P = 0.01), never-smokers (55.26%, P = 0.004), and those with lung adenocarcinoma (ADC) (52.17%, P |
| doi_str_mv | 10.1016/j.anndiagpath.2020.151633 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2446670349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1092913420301799</els_id><sourcerecordid>2446670349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-1bed1e447ba570916eb3726a3530ff4ac8c0ad66b408fe60b626c6b1ce5f8f643</originalsourceid><addsrcrecordid>eNqNkE1rGzEQhkVJqZ20f6Eot1zW1ddKu8dg7DRgKJS2V6HVjlw5u1pH0hby7yvjJOSYizSI59XMPAhdU7KihMpvh5UJofdmfzT574oRVt5rKjn_gJa05qxqaNtclJq0rGopFwt0mdKBEEpFrT6hBWetUozXS2T-mGEGPDmcIM4jzvM4RTya-AAxYVfqY4Te2-zDHm_utj_xOGeT_RQS9gGHKVRpNMOALZRjmAtlTbBQcoWCkNNn9NGZIcGX5_sK_d5ufq2_V7sfd_fr211luVK5oh30FIRQnakVaamEjismDa85cU4Y21hieik7QRoHknSSSSs7aqF2jZOCX6Gb87_HOD3OkLIefTpNZQJMc9JMCCkV4aItaHtGbZxSiuD0Mfqy85OmRJ8M64N-Y1ifDOuz4ZL9-txm7kboX5MvSguwPgNQlv3nIepkiwhbLEawWfeTf0eb_4Dkk2M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446670349</pqid></control><display><type>article</type><title>Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients</title><source>Elsevier ScienceDirect Journals</source><creator>Wen, Linfang ; Wang, Shenghao ; Xu, Weiran ; Xu, Xiaofeng ; Li, Mei ; Zhang, Yaqiong ; Du, Xiaobing ; Liu, Shuang</creator><creatorcontrib>Wen, Linfang ; Wang, Shenghao ; Xu, Weiran ; Xu, Xiaofeng ; Li, Mei ; Zhang, Yaqiong ; Du, Xiaobing ; Liu, Shuang</creatorcontrib><description>We investigated whether serum tumor markers (STMs) represent a valuable noninvasive tool to predict epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients.
A retrospective analysis was performed for 143 NSCLC patients at the Peking University International Hospital from December 2014 to December 2019. EGFR mutations in the tumor tissues were identified by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and next generation sequencing (NGS). The relationships between EGFR mutation and several clinicopathological features were analyzed.
EGFR mutation were found more frequently in female (56.67%, P = 0.01), never-smokers (55.26%, P = 0.004), and those with lung adenocarcinoma (ADC) (52.17%, P < 0.001). The positive mutation rate for the EGFR gene were higher in the squamous cell carcinoma antigen (SCCA)group (≤1.5 ng/ml) and in the gastrin-releasing peptide precursor (preGRP) increased group (≥69.2 pg/ml), and this difference was statistically significant (P < 0.05). Univariate logistic regression analysis demonstrated that females (Odd ratio [OR]: 2.435, 95% confidence interval [CI]: 1.232, 4.813, P = 0.01) and never-smokers (OR = 0.370; CI = 0.186, 0.734; P = 0.004), lung adenocarcinoma patients (OR = 9.091; CI = 2.599, 21.800; P = 0.001), the SCC group (≤1.5 ng/ml) (OR = 0.331, CI = 0.120, 0.914; P = 0.033), and the preGRP group (≥69.2 pg/ml) (OR = 5.478, CI = 1.462, 20.528; P = 0.012) patients were risk factors for EGFR gene mutation. Multivariate logistic regression analysis demonstrated that lung ADC and proGRP elevation were independent risk factors for predicting EGFR gene positivity (P < 0.05).
STMs are associated with mutant EGFR status and could be integrated with other clinical factors to facilitate the classification of EGFR mutation status among NSCLC patients.
•STMs are associated with mutant EGFR status.•STMs represent a valuable noninvasive tool to predict EGFR mutations in NSCLC patients.•STMs could be integrated with other clinical factors to facilitate the classification of EGFR mutation status.</description><identifier>ISSN: 1092-9134</identifier><identifier>EISSN: 1532-8198</identifier><identifier>DOI: 10.1016/j.anndiagpath.2020.151633</identifier><identifier>PMID: 32977235</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>EGFR mutations ; Non-small cell lung cancer ; Serum tumor markers</subject><ispartof>Annals of diagnostic pathology, 2020-12, Vol.49, p.151633-151633, Article 151633</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-1bed1e447ba570916eb3726a3530ff4ac8c0ad66b408fe60b626c6b1ce5f8f643</citedby><cites>FETCH-LOGICAL-c377t-1bed1e447ba570916eb3726a3530ff4ac8c0ad66b408fe60b626c6b1ce5f8f643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1092913420301799$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32977235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wen, Linfang</creatorcontrib><creatorcontrib>Wang, Shenghao</creatorcontrib><creatorcontrib>Xu, Weiran</creatorcontrib><creatorcontrib>Xu, Xiaofeng</creatorcontrib><creatorcontrib>Li, Mei</creatorcontrib><creatorcontrib>Zhang, Yaqiong</creatorcontrib><creatorcontrib>Du, Xiaobing</creatorcontrib><creatorcontrib>Liu, Shuang</creatorcontrib><title>Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients</title><title>Annals of diagnostic pathology</title><addtitle>Ann Diagn Pathol</addtitle><description>We investigated whether serum tumor markers (STMs) represent a valuable noninvasive tool to predict epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients.
A retrospective analysis was performed for 143 NSCLC patients at the Peking University International Hospital from December 2014 to December 2019. EGFR mutations in the tumor tissues were identified by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and next generation sequencing (NGS). The relationships between EGFR mutation and several clinicopathological features were analyzed.
EGFR mutation were found more frequently in female (56.67%, P = 0.01), never-smokers (55.26%, P = 0.004), and those with lung adenocarcinoma (ADC) (52.17%, P < 0.001). The positive mutation rate for the EGFR gene were higher in the squamous cell carcinoma antigen (SCCA)group (≤1.5 ng/ml) and in the gastrin-releasing peptide precursor (preGRP) increased group (≥69.2 pg/ml), and this difference was statistically significant (P < 0.05). Univariate logistic regression analysis demonstrated that females (Odd ratio [OR]: 2.435, 95% confidence interval [CI]: 1.232, 4.813, P = 0.01) and never-smokers (OR = 0.370; CI = 0.186, 0.734; P = 0.004), lung adenocarcinoma patients (OR = 9.091; CI = 2.599, 21.800; P = 0.001), the SCC group (≤1.5 ng/ml) (OR = 0.331, CI = 0.120, 0.914; P = 0.033), and the preGRP group (≥69.2 pg/ml) (OR = 5.478, CI = 1.462, 20.528; P = 0.012) patients were risk factors for EGFR gene mutation. Multivariate logistic regression analysis demonstrated that lung ADC and proGRP elevation were independent risk factors for predicting EGFR gene positivity (P < 0.05).
STMs are associated with mutant EGFR status and could be integrated with other clinical factors to facilitate the classification of EGFR mutation status among NSCLC patients.
•STMs are associated with mutant EGFR status.•STMs represent a valuable noninvasive tool to predict EGFR mutations in NSCLC patients.•STMs could be integrated with other clinical factors to facilitate the classification of EGFR mutation status.</description><subject>EGFR mutations</subject><subject>Non-small cell lung cancer</subject><subject>Serum tumor markers</subject><issn>1092-9134</issn><issn>1532-8198</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkE1rGzEQhkVJqZ20f6Eot1zW1ddKu8dg7DRgKJS2V6HVjlw5u1pH0hby7yvjJOSYizSI59XMPAhdU7KihMpvh5UJofdmfzT574oRVt5rKjn_gJa05qxqaNtclJq0rGopFwt0mdKBEEpFrT6hBWetUozXS2T-mGEGPDmcIM4jzvM4RTya-AAxYVfqY4Te2-zDHm_utj_xOGeT_RQS9gGHKVRpNMOALZRjmAtlTbBQcoWCkNNn9NGZIcGX5_sK_d5ufq2_V7sfd_fr211luVK5oh30FIRQnakVaamEjismDa85cU4Y21hieik7QRoHknSSSSs7aqF2jZOCX6Gb87_HOD3OkLIefTpNZQJMc9JMCCkV4aItaHtGbZxSiuD0Mfqy85OmRJ8M64N-Y1ifDOuz4ZL9-txm7kboX5MvSguwPgNQlv3nIepkiwhbLEawWfeTf0eb_4Dkk2M</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Wen, Linfang</creator><creator>Wang, Shenghao</creator><creator>Xu, Weiran</creator><creator>Xu, Xiaofeng</creator><creator>Li, Mei</creator><creator>Zhang, Yaqiong</creator><creator>Du, Xiaobing</creator><creator>Liu, Shuang</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202012</creationdate><title>Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients</title><author>Wen, Linfang ; Wang, Shenghao ; Xu, Weiran ; Xu, Xiaofeng ; Li, Mei ; Zhang, Yaqiong ; Du, Xiaobing ; Liu, Shuang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-1bed1e447ba570916eb3726a3530ff4ac8c0ad66b408fe60b626c6b1ce5f8f643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>EGFR mutations</topic><topic>Non-small cell lung cancer</topic><topic>Serum tumor markers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wen, Linfang</creatorcontrib><creatorcontrib>Wang, Shenghao</creatorcontrib><creatorcontrib>Xu, Weiran</creatorcontrib><creatorcontrib>Xu, Xiaofeng</creatorcontrib><creatorcontrib>Li, Mei</creatorcontrib><creatorcontrib>Zhang, Yaqiong</creatorcontrib><creatorcontrib>Du, Xiaobing</creatorcontrib><creatorcontrib>Liu, Shuang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of diagnostic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wen, Linfang</au><au>Wang, Shenghao</au><au>Xu, Weiran</au><au>Xu, Xiaofeng</au><au>Li, Mei</au><au>Zhang, Yaqiong</au><au>Du, Xiaobing</au><au>Liu, Shuang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients</atitle><jtitle>Annals of diagnostic pathology</jtitle><addtitle>Ann Diagn Pathol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>49</volume><spage>151633</spage><epage>151633</epage><pages>151633-151633</pages><artnum>151633</artnum><issn>1092-9134</issn><eissn>1532-8198</eissn><abstract>We investigated whether serum tumor markers (STMs) represent a valuable noninvasive tool to predict epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients.
A retrospective analysis was performed for 143 NSCLC patients at the Peking University International Hospital from December 2014 to December 2019. EGFR mutations in the tumor tissues were identified by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and next generation sequencing (NGS). The relationships between EGFR mutation and several clinicopathological features were analyzed.
EGFR mutation were found more frequently in female (56.67%, P = 0.01), never-smokers (55.26%, P = 0.004), and those with lung adenocarcinoma (ADC) (52.17%, P < 0.001). The positive mutation rate for the EGFR gene were higher in the squamous cell carcinoma antigen (SCCA)group (≤1.5 ng/ml) and in the gastrin-releasing peptide precursor (preGRP) increased group (≥69.2 pg/ml), and this difference was statistically significant (P < 0.05). Univariate logistic regression analysis demonstrated that females (Odd ratio [OR]: 2.435, 95% confidence interval [CI]: 1.232, 4.813, P = 0.01) and never-smokers (OR = 0.370; CI = 0.186, 0.734; P = 0.004), lung adenocarcinoma patients (OR = 9.091; CI = 2.599, 21.800; P = 0.001), the SCC group (≤1.5 ng/ml) (OR = 0.331, CI = 0.120, 0.914; P = 0.033), and the preGRP group (≥69.2 pg/ml) (OR = 5.478, CI = 1.462, 20.528; P = 0.012) patients were risk factors for EGFR gene mutation. Multivariate logistic regression analysis demonstrated that lung ADC and proGRP elevation were independent risk factors for predicting EGFR gene positivity (P < 0.05).
STMs are associated with mutant EGFR status and could be integrated with other clinical factors to facilitate the classification of EGFR mutation status among NSCLC patients.
•STMs are associated with mutant EGFR status.•STMs represent a valuable noninvasive tool to predict EGFR mutations in NSCLC patients.•STMs could be integrated with other clinical factors to facilitate the classification of EGFR mutation status.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32977235</pmid><doi>10.1016/j.anndiagpath.2020.151633</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1092-9134 |
| ispartof | Annals of diagnostic pathology, 2020-12, Vol.49, p.151633-151633, Article 151633 |
| issn | 1092-9134 1532-8198 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2446670349 |
| source | Elsevier ScienceDirect Journals |
| subjects | EGFR mutations Non-small cell lung cancer Serum tumor markers |
| title | Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A02%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Value%20of%20serum%20tumor%20markers%20for%20predicting%20EGFR%20mutations%20in%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=Annals%20of%20diagnostic%20pathology&rft.au=Wen,%20Linfang&rft.date=2020-12&rft.volume=49&rft.spage=151633&rft.epage=151633&rft.pages=151633-151633&rft.artnum=151633&rft.issn=1092-9134&rft.eissn=1532-8198&rft_id=info:doi/10.1016/j.anndiagpath.2020.151633&rft_dat=%3Cproquest_cross%3E2446670349%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446670349&rft_id=info:pmid/32977235&rft_els_id=S1092913420301799&rfr_iscdi=true |